Targeting the tumor-stromal-immune cell axis.

Murali Gururajan,Leland W.K Chung,Sajni Josson

doi:10.18632/oncoscience.190

Abstract

Targeting the tumor-stromal-immune cell axis.

Highlights

Therapeutic targeting of Cancer associated fibroblasts (CAFs) with an anti-fibrotic agent, tranilast, led to reduced infiltration of immune suppressive cell types, including regulatory T cells and myeloid derived suppressor cells (MDSCs) in the tumor microenvironment (TME) in preclinical immune-competent mouse models of lung cancer, melanoma and lymphoma [6]
Www.impactjournals.com/oncoscience with dendritic cell-based vaccines only in mice with an intact immune system [6]. These data in aggregate indicate that systemic anti-tumor immune responses are better elicited when barriers in TME are disrupted, including CAF-targeted therapy
It will be interesting to explore the effects of CAF targeted therapies and/or low dose radiation for enhancing the antitumor efficacy of checkpoint inhibitors

Summary

Introduction

Therapeutic targeting of CAFs with an anti-fibrotic agent, tranilast, led to reduced infiltration of immune suppressive cell types, including regulatory T cells and MDSCs in the TME in preclinical immune-competent mouse models of lung cancer, melanoma and lymphoma [6]. Www.impactjournals.com/oncoscience with dendritic cell-based vaccines only in mice with an intact immune system [6]. These data in aggregate indicate that systemic anti-tumor immune responses are better elicited when barriers in TME are disrupted, including CAF-targeted therapy.

Results

Conclusion